ArticleScientific reports2017

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bin Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.